With men often finding it easier to talk tactics than testes, the comedian issues an open invitation to join a star-studded squad.
Sleeping well at night may help to protect men from deadly prostate cancer, a study has found.
Former footballer Vinnie Jones has revealed he has been diagnosed with skin cancer, describing the disease as his 'scariest opponent yet'.
UK doctors have launched a new trial which offers a new type of molecular radiotherapy - never before tested in children - for one of the deadliest childhood cancers. The new treatment uses radiotherapy which piggy-backs on a drug that naturally attaches itself to neuroblastoma cells.
Neuroblastoma is usually diagnosed in children aged five and under, and the aggressive form of the disease remains very difficult to treat successfully. Around 24 patients between 18 months and 18 years old will be treated in the LuDO neuroblastoma trial, at University College Hospital, London.
The treatment will be delivered directly to the tumour in up to four courses once every eight weeks. This treatment is effective in adults with other cancer types, but this is the first time it has been tried in children with neuroblastoma.
– Dr Richard Clarkson from Cardiff University's European Cancer Stem Cell Research Institute
We showed that suppressing this gene reduced the spread of cancer by more than 80%.
Our next goal was to then find a way to suppress Bcl3 pharmacologically. Despite great improvements in therapy of early stage breast cancer, the current therapeutic options for patients with late stage metastatic disease are limited.
There is therefore a clear unmet clinical need to identify new drugs to reverse or at least to slow down disease progression.
An experimental drug that can virtually halt the deadly spread of breast cancer has been tested by scientists.
Researchers are now working with a biotechnology company to prepare the compound for patient trials.
The new research builds on previous studies of a gene called Bc13 that appears to play a critical role in the spread of breast cancer.
Scientists at Cardiff University conducted computer simulations to work out how Bc13 functioned and then blocked it.
In tests on mice, the researchers first deleted the gene and then explored ways of inhibiting it with a drug.They found the right candidate compound by screening a library of chemicals until one was found that could target Bc13.
When mice with metastatic breast cancer were treated with the compound, the spread of tumours to the lungs and other parts of the body was dramatically reduced.
The British Medical Association (BMA) has said the profession must "guarantee" that older cancer patients "are treated with care and respect" after claims some are denied treatment solely on their age.
– Dr Mark Porter, the BMA's chairman of council
It is important that all healthcare professionals ensure that patients are treated on the basis of their clinical need.
With an increasingly ageing population, it should be a key part of medical professionalism to guarantee that older patients are treated with the care and respect they deserve.
Macmillan Cancer Support said health workers should ensure decisions over cancer treatment take into account a patient's physical and mental health and not be based on age alone.
The National Cancer Intelligence Network (NCIN), which carried out the research into pensioner survival rates alongside the charity, joined the call for wider assessment.
NCIN's clinical lead Dr Mick Peake said: "It is vital that all patients receive the best and most effective treatment based on the nature of their cancer and their fitness for treatment and that chronological age alone is not the deciding factor.
"We know that cancer survival rates in older patients in many other countries are better than in the UK and ensuring optimal treatment at all ages is the way of tackling this issue."
A leading charity has warned cancer patients are being "written off" as being too old for treatment, saying assessments are ignoring fitness levels to judge on age alone.
Macmillan Cancer Support spoke out after finding more than 130,000 pensioners who have been diagnosed with cancer have gone on to live for at least a decade, including 8,000 patents over the age of 80.
The charity's chief executive, Ciaran Devane, said: "With a proper assessment and appropriate treatment, our research shows that many older cancer patients can live for a long time and can even be cured.
"The barriers to getting treatment - which include age discrimination and inadequate assessment methods - must be tackled now so more older people can survive cancer and live for many years."
The Department of Health said they expect the NHS to provide approved drugs to those who need them after a report by health experts claimed that one third of patients with kidney cancer have been denied life-treating medicine.
– Department of Health spokesman
Patients have a right to drugs and treatments that have been approved by Nice and we expect the NHS to provide them if they are needed.
That is why the chief executive of the NHS has written to the local NHS requiring them to publish which NHS organisations are funding and using drugs and treatments approved by Nice, and which are not.
A third of patients with kidney cancer have been denied life-saving drugs despite hospitals being told to prescribe them which has exposed an "endemic and disastrous postcode lottery" of care within the health service, experts have said.
A report by the Health and Social Care Information Centre looked at the NHS's use of 10 common drugs during 2012 which have been approved by Government advisory watchdog the National Institute for Health and Care Excellence (Nice).
One in three people suffering from kidney cancer were not given the life-extending drugs sunitinib or pazopanib, the report found. It also found that one in three motor neurone disease patients did not receive riluzole - the only treatment for the condition.
Chief executive of the Rarer Cancers Foundation Andrew Wilson told The Daily Telegraph that patients were suffering from "an endemic postcode lottery" of care in access to certain medicines.
He said: "It is extremely worrying that the NHS does not seem to be making available cancer treatments to all patients who could benefit, even when the drug is approved by Nice."